Repligen Corp (RGEN) concluded trading on Wednesday at a closing price of $154.70, with 0.44 million shares of worth about $67.77 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 27.90% during that period and on January 08, 2025 the price saw a gain of about 0.78%. Currently the company’s common shares owned by public are about 56.03M shares, out of which, 52.13M shares are available for trading.
Stock saw a price change of 7.48% in past 5 days and over the past one month there was a price change of 3.69%. Year-to-date (YTD), RGEN shares are showing a performance of 7.48% which decreased to -12.54% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $113.50 but also hit the highest price of $211.13 during that period. The average intraday trading volume for Repligen Corp shares is 571.43K. The stock is currently trading 3.00% above its 20-day simple moving average (SMA20), while that difference is up 6.40% for SMA50 and it goes to 4.10% higher than SMA200.
Repligen Corp (NASDAQ: RGEN) currently have 56.03M outstanding shares and institutions hold larger chunk of about 99.86% of that.
The stock has a current market capitalization of $8.67B and its 3Y-monthly beta is at 0.97. It has posted earnings per share of -$0.15 in the same period. It has Quick Ratio of 8.76 while making debt-to-equity ratio of 0.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RGEN, volatility over the week remained 4.75% while standing at 4.07% over the month.
Stock’s fiscal year EPS is expected to drop by -11.96% while it is estimated to increase by 13.23% in next year. EPS is likely to grow at an annualized rate of 21.00% for next 5-years, compared to annual growth of 11.56% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Canaccord Genuity on December 17, 2024 offering a Hold rating for the stock and assigned a target price of $165 to it. On August 28, 2024, Wells Fargo Initiated their recommendations, while on June 26, 2024, Deutsche Bank Upgrade their ratings for the stock with a price target of $155. Stock get a Neutral rating from Guggenheim on June 18, 2024.
